Review

. 2022 Oct 1;7(1):25.

doi: 10.1186/s41181-022-00177-w.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jun Toyohara¹, Mohammed Al-Qahtani², Ya-Yao Huang³, Emiliano Cazzola^{4

5}, Sergio Todde⁶, Shozo Furumoto⁷, Renata Mikolajczak^{8

9}, Clemens Decristoforo¹⁰, Nic Gillings¹¹, Min Yang¹², Raymond Reilly¹³, Adriano Duatti^{14

15}, Antonia Denkova¹⁶, Ralf Schirrmacher¹⁷, Giuseppe Carlucci¹⁸, Yann Seimbille¹⁹, Zhaofei Liu²⁰, Beverley Ellis²¹, Bart T Cornelissen²², Klaus Kopka²³, Emerson Bernardes^{24

25}

Affiliations

¹ PET Radiopharmaceutical Sciences, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
² Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
³ Molecular Imaging Center, National Taiwan University, Taipei, Taiwan.
⁴ Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Sacro Cuore-Don Calabria Hospital, Negrar (Vr), Italy.
⁵ Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Sacro Cuore-Don Calabria, Negrar (Vr), Italia.
⁶ University of Milano-Bicocca, Tecnomed Foundation, Monza, Italy.
⁷ Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan.
⁸ Radioisotope Centre POLATOM, National Centre for Nuclear Research (NCBJ), Otwock, Poland.
⁹ Ośrodek Radioizotopów POLATOM, NARODOWE CENTRUM BADAŃ JĄDROWYCH (NCBJ), Otwock, Poland.
¹⁰ Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
¹¹ Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
¹² NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
¹³ Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
¹⁴ Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
¹⁵ Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie Università di Ferrara, Ferrara, Italia.
¹⁶ Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands.
¹⁷ Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
¹⁸ Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
¹⁹ Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
²⁰ Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Centre, Beijing, China.
²¹ Manchester University NHS Foundation Trust, Manchester, UK.
²² Department of Nuclear Medicine and Molecular Imaging, Groningen (UMCG), University Medical Center, University of Groningen, Groningen, The Netherlands.
²³ Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. k.kopka@hzdr.de.
²⁴ Energy and Nuclear Research Institute (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brazil.
²⁵ Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brasil.

PMID: 36182995
PMCID: PMC9526771
DOI: 10.1186/s41181-022-00177-w

Review

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jun Toyohara et al. EJNMMI Radiopharm Chem. 2022.

. 2022 Oct 1;7(1):25.

doi: 10.1186/s41181-022-00177-w.

Authors

Affiliations

¹ PET Radiopharmaceutical Sciences, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
² Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
³ Molecular Imaging Center, National Taiwan University, Taipei, Taiwan.
⁴ Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Sacro Cuore-Don Calabria Hospital, Negrar (Vr), Italy.
⁵ Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Sacro Cuore-Don Calabria, Negrar (Vr), Italia.
⁶ University of Milano-Bicocca, Tecnomed Foundation, Monza, Italy.
⁷ Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan.
⁸ Radioisotope Centre POLATOM, National Centre for Nuclear Research (NCBJ), Otwock, Poland.
⁹ Ośrodek Radioizotopów POLATOM, NARODOWE CENTRUM BADAŃ JĄDROWYCH (NCBJ), Otwock, Poland.
¹⁰ Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
¹¹ Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
¹² NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
¹³ Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
¹⁴ Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
¹⁵ Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie Università di Ferrara, Ferrara, Italia.
¹⁶ Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands.
¹⁷ Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
¹⁸ Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
¹⁹ Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
²⁰ Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Centre, Beijing, China.
²¹ Manchester University NHS Foundation Trust, Manchester, UK.
²² Department of Nuclear Medicine and Molecular Imaging, Groningen (UMCG), University Medical Center, University of Groningen, Groningen, The Netherlands.
²³ Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. k.kopka@hzdr.de.
²⁴ Energy and Nuclear Research Institute (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brazil.
²⁵ Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brasil.

PMID: 36182995
PMCID: PMC9526771
DOI: 10.1186/s41181-022-00177-w

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Main body: This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

Conclusion: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry.

Keywords: Highlight Articles; Nuclear Medicine; Radiochemistry; Radiopharmaceutical Sciences; Radiopharmacy; Trends in Radiopharmaceutical Sciences.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

**Fig. 1**
On-column conversion of [¹¹C]CH₃I to [¹¹C]HCN (with permission from CCC Marketplace)

**Fig. 2**
Optimised automation conditions for the production of [¹⁸F]FMZ (Reproduced with permission (Gendron et al. 2022))

**Fig. 3**
A new [¹⁸F]difluorocarbene reagent (A) and its application to the ¹⁸F-difluoromethylation reactions of (thio)phenols and N-heterocycles (B) and aryl boronic acids (C)

**Fig. 4**
Whole-body PET images of a patient at various times after injection of ⁸⁹Zr-Df-IAB22M2C with good visualization of uptake in the nodal metastasis at 24–48 h post-injection. Reproduced from Farwell et al. (2022)

**Fig. 5**
Comparison between OncoFAP left and FAP-46 right, for two different patients both having breast cancer. The images show very similar behaviour of the tracers (with permission from Backhaus et al. 2022)

**Fig. 6**
a, b, Structure of GGGGK-HYNIC and [^99mTc]Tc-NB4. c Synthetic route of [^99mTc]Tc-NB4 (with permission from Liu et al., 2022)

**Fig. 7**
Representative image of SST₂ receptor staining for HEK and HEKsst2 cells after stimulation by increasing concentrations of 5-aza-dC and constant concentrations of VPA. Non-stimulated HEKsst2 and HEK cells are shown as a reference (40× magnification). The figure is reproduced with permission from Kotzerke et al. (2022)

**Fig. 8**
(a) Cellular uptake of [¹⁷⁷Lu]Lu-DOTA-TATE (50 kBq) for 1 h in HEKsst2 and PC3 cells and (b) 24 h. Before uptake analysis both cell lines were pretreated with 5-aza-dC and VPA over a time period of 5 days as described above. Unstimulated controls (con) were simultaneously incubated with [¹⁷⁷Lu]Lu-DOTA-TATE. The intracellular activity is normalized to results in unstimulated control cells. Results are expressed as changes in percentage in relation to results without stimulation. All data are shown as mean ± SD. The figure is reproduced with permission (Kotzerke et al. 2022)

**Fig. 9**
Over the last 8 decades several combinatorial strategies have been repeatedly studied for the management of cancer and will continue being improved by the emergence of new chemotherapeutic drugs, precision medicine technology, lead targets and ligands

See this image and copyright information in PMC

References

1. Avila-Rodriguez MA, Jalilian AR, Korde A, Schlyer D, Haji-Saeid M, Paez J, Perez-Pijuan Current status on cyclotron facilities and related infrastructure supporting PET applications in Latin America and the Caribbean. EJNMMI Radiopharm Chem. 2022;7:14. doi: 10.1186/s41181-022-00166-z. - DOI - PMC - PubMed
1. Backhaus P, Gierse F, Burg MC, Büther F, Asmus I, Dorten P, Cufe J, Roll W, Neri D, Cazzamalli S, Millul J, Mock J, Galbiati A, Zana A, Schäfers KP, Hermann S, Weckesser M, Tio J, Wagner S, Breyholz HJ, Schäfers M. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Molec Imag. 2022;49:1822–32. doi: 10.1007/s00259-021-05653-0. - DOI - PMC - PubMed
1. Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Koester U, Schibli R, van der Meulen N, Mueller C. Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49(4):1113–26. doi: 10.1007/s00259-021-05564-0. - DOI - PMC - PubMed
1. Cai Z, Yook S, Lu Y, Bergstrom D, Winnik MA, Pignol JP, Reilly RM. Local radiation treatment of HER2-positive breast cancer using trastuzumab-modified gold nanoparticles labeled with 177Lu. Pharm Res. 2017;34:579–90. doi: 10.1007/s11095-016-2082-2. - DOI - PubMed
1. Dietlein F, Kobe C, Vazquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumauier B, Schomacker K, Drzezga AE, Dietlein M. An 89Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients. J Nucl Med. 2022;63:573–83. doi: 10.2967/jnumed.121.262290. - DOI - PubMed

Publication types

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- eScholarship, University of California - Access Free Full Text

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Affiliations

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources